论文部分内容阅读
目的:观察MMED化疗方案治疗B淋巴细胞来源的复发难治性急性淋巴细胞白血病与非霍奇金淋巴瘤的疗效和安全性。方法:2004年9月至2006年9月我科收治的10例复发难治性急性淋巴细胞白血病与16例复发难治性非霍奇金淋巴瘤患者,免疫分型均为B细胞来源,接受MMED(米托蒽醌6mg/d静滴,第1天到第3天,甲氨喋呤100mg/d静滴,第1天和第8天;足叶乙甙100mg/d静滴,第1天到第5天;地塞米松10mg/d静滴,第1天到第8天)方案化疗。结果:复发难治性急性淋巴细胞白血病完全缓解率30.0%,部分缓解率50.0%,总有效率80%。难治复发性非霍奇金淋巴瘤完全缓解率37.5%,部分缓解率50.0%,总有效率87.5%。主要不良反应为不同程度的骨髓抑制,无口腔黏膜溃疡发生,脏器毒性反应轻微。结论:MMED化疗方案对B淋巴细胞来源的复发难治性急性淋巴细胞白血病与非霍奇金淋巴瘤有较好的疗效,毒性反应轻微。
Objective: To observe the efficacy and safety of MMED chemotherapy in the treatment of B lymphocyte-derived relapsed and refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. Methods: From September 2004 to September 2006, 10 patients with recurrent refractory acute lymphoblastic leukemia and 16 patients with recurrent refractory non-Hodgkin’s lymphoma were enrolled in our department. The immunophenotypes were all B cells. MMED (mitoxantrone 6mg / d intravenous infusion, day 1 to day 3, methotrexate 100mg / d intravenous infusion, the first day and the eighth day; etoposide 100mg / d intravenous infusion, the first Day to day 5; dexamethasone 10mg / d intravenous infusion, day 1 to day 8) regimen chemotherapy. Results: The complete remission rate of relapsed and refractory acute lymphoblastic leukemia was 30.0%, the partial remission rate was 50.0% and the total effective rate was 80%. The complete remission rate of refractory recurrent non-Hodgkin’s lymphoma was 37.5%, the partial remission rate was 50.0% and the total effective rate was 87.5%. The main adverse reactions were different degrees of myelosuppression, no occurrence of oral mucosal ulcers, organ toxicity minor. Conclusion: MMED chemotherapy regimen has good curative effect on B lymphocyte-derived relapsed-refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma with mild toxicity.